Form 4: Mineralys CFO Sells Shares Under 10b5-1 Plan

Mineralys Therapeutics CFO Adam Levy sold over 10,000 shares of common stock for approximately $450,000 through a pre-arranged 10b5-1 trading plan.

Summary

• Adam Scott Levy, CFO and Secretary of Mineralys Therapeutics, Inc. (MLYS), reported transactions on October 13, 2025.
• He sold a total of 10,758 shares of common stock (7,366 shares and 3,392 shares).
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 14, 2023.
• The first block of 7,366 shares was sold at a weighted-average price of $41.9021, with prices ranging from $41.1362 to $42.1300.
• The second block of 3,392 shares was sold at a weighted-average price of $42.2561, with prices ranging from $42.1600 to $42.3400.
• Following these transactions, Levy beneficially owns 116,865 shares of common stock directly.
• Additionally, 5,311 shares were transferred to an ex-spouse pursuant to a domestic relations order since the last ownership report and are no longer reported as beneficially owned by Levy.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the transactions were pre-planned under a 10b5-1 plan, mitigating concerns about trading on adverse non-public information. It's a routine personal financial management disclosure.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were not based on new, non-public information.
• Shares were sold at a relatively strong price range of $41.1362 to $42.3400.

Negatives

• A key executive (CFO) reduced their direct ownership in the company by a notable amount (10,758 shares).
• The total value of shares sold exceeds $450,000, representing a significant divestment.

Risks

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially leading to short-term downward pressure on the stock price.
• A reduction in insider ownership might be interpreted by some investors as a lack of confidence, though the 10b5-1 plan mitigates this interpretation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports insider trading activity.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to the Issuer, any securityholder, or the SEC staff.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape. Insider sales, even pre-planned, are common across industries for personal financial management.

Comparison to Industry Standards

• This filing is a standard disclosure of insider trading activity (Form 4) and does not contain information that allows for a direct comparison of company performance or results against global benchmarks or specific comparable companies/projects. The transaction itself, being under a 10b5-1 plan, aligns with best practices for insiders managing their equity holdings while avoiding accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, which could be interpreted in various ways, though the 10b5-1 plan provides context.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company. It is a historical report of transactions.

Key Dates

Recommendation

The filing reports insider selling by the CFO, Adam Scott Levy, under a pre-arranged 10b5-1 trading plan. While insider selling reduces direct ownership, the pre-planned nature suggests it's for personal financial management rather than a reaction to negative company-specific news. Without additional company-specific financial or operational updates, this filing alone does not provide a strong signal for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, awaiting further fundamental information.

Keywords

Mineralys Therapeutics, MLYS, Adam Scott Levy, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction